REGN

Regeneron Pharmaceuticals, Inc.

HealthcareBiotechnologyNASDAQ

$614.78

-$26.61 (-4.33%)today

Conviction

0/ 10

Fair Value$873.20

Upside+42.03%

Signal0

Market Cap$79.2B

52W Range$476.49–$821.11

Next EarningsApr 29

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$787.68

Current Price$732.87

Upside / Down+7.5%

P(Undervalued)64.0%

P(20%+ Up)29.5%

P(15%+ Down)13.1%

Fair Value Distribution — percentile bands

64.0% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

1.8%/yr

±4.9% · revenue growth to justify current price

FCF-Based Reverse DCF

-6.1%/yr

±3.0% · FCF growth to justify current price

THE GAP

Market pricing margin expansion or capex normalization

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Quick Take

Regeneron Pharmaceuticals, Inc.

Trailing P/E18.2x

Forward P/E14.3x

P/S5.5x

EPS (TTM)$41.44

Analyst Target$873.20

Analyst Upside42.0%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kMar 1

Conviction: unchanged

Regeneron 2025 10-K: EYLEA Biosimilar Headwind, Dupixent Strength, Execution Risks on Pipeline

REGN FY2025 10-K: Bifurcated portfolio — EYLEA biosimilar-driven structural decline (-17% YoY combined sales) partially offset by Dupixent growth (+26%). Margins pressured by high Sanofi profit-share ...